Flavokawain B is primarily studied for its potential anticancer properties. It has shown activity against various cancer cell lines, including breast, prostate, liver, and colon cancers, by inducing apoptosis and inhibiting cell cycle progression. Research indicates it may suppress tumor growth by modulating key signaling pathways such as NF-κB, PI3K/Akt, and MAPK. It also exhibits anti-inflammatory effects by reducing the production of pro-inflammatory cytokines, suggesting possible use in managing chronic inflammatory conditions. Additionally, Flavokawain B has demonstrated antimicrobial activity against certain pathogens, making it a candidate for development in infectious disease treatment. Due to its natural origin and bioactivity, it is being explored as a lead compound in nutraceuticals and pharmaceuticals, particularly for cancer prevention and therapy. However, most evidence comes from in vitro and animal studies, so clinical applications remain under investigation.